{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:55:13Z","timestamp":1791312913050,"version":"4.3.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s12325-014-0119-7","type":"journal-article","created":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T07:51:37Z","timestamp":1399881097000},"page":"473-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and Results"],"prefix":"10.1007","volume":"31","author":[{"given":"Alexander T.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Imfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,13]]},"reference":[{"key":"119_CR1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1160\/TH07-03-0212","volume":"98","author":"AT Cohen","year":"2007","unstructured":"Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756\u201364.","journal-title":"Thromb Haemost"},{"key":"119_CR2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/ATVBAHA.108.162545","volume":"28","author":"JA Heit","year":"2008","unstructured":"Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28:370\u20132.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"119_CR3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","volume":"165","author":"AM Holbrook","year":"2005","unstructured":"Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095\u2013106.","journal-title":"Arch Intern Med"},{"key":"119_CR4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","volume":"1","author":"DW Barritt","year":"1960","unstructured":"Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet. 1960;1:1309\u201312.","journal-title":"Lancet"},{"key":"119_CR5","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S\u201394S.","journal-title":"Chest"},{"key":"119_CR6","doi-asserted-by":"crossref","unstructured":"Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006:CD001367.","DOI":"10.1002\/14651858.CD001367.pub2"},{"key":"119_CR7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(11)61505-5","volume":"379","author":"HR Buller","year":"2012","unstructured":"Buller HR, Gallus AS, Pillion G, Prins MH, Raskob GE, Cassiopea I. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012;379:123\u20139.","journal-title":"Lancet"},{"key":"119_CR8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","volume":"357","author":"I Gogh van","year":"2007","unstructured":"van Gogh I, Buller HR, Cohen AT, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007;357:1094\u2013104.","journal-title":"N Engl J Med"},{"key":"119_CR9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199709043371002","volume":"337","author":"G Simonneau","year":"1997","unstructured":"Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: evaluations dans l\u2019Embolie Pulmonaire. N Engl J Med. 1997;337:663\u20139.","journal-title":"N Engl J Med"},{"key":"119_CR10","unstructured":"NICE. Treating venous thromboembolism. National Clinical Guideline Centre 2012."},{"key":"119_CR11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.thromres.2011.04.011","volume":"128","author":"H Moualla","year":"2011","unstructured":"Moualla H, Garcia D. Vitamin K antagonists\u2013current concepts and challenges. Thromb Res. 2011;128:210\u20135.","journal-title":"Thromb Res"},{"issue":"3 Suppl","key":"119_CR12","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","volume":"126","author":"J Ansell","year":"2004","unstructured":"Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):204S\u201333S.","journal-title":"Chest"},{"key":"119_CR13","unstructured":"NICE. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 261. National Clinical Guideline Centre 2012."},{"key":"119_CR14","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1111\/j.1538-7836.2004.00957.x","volume":"2","author":"SR Kahn","year":"2004","unstructured":"Kahn SR, M\u2019Lan CE, Lamping DL, et al. The influence of venous thromboembolism on quality of life and severity of chronic venous disease. J Thromb Haemost. 2004;2:2146\u201351.","journal-title":"J Thromb Haemost"},{"key":"119_CR15","doi-asserted-by":"crossref","first-page":"e120S","DOI":"10.1378\/chest.11-2294","volume":"141","author":"JI Weitz","year":"2012","unstructured":"Weitz JI, Eikelboom JW, Samama MM, American College of Chest. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e120S\u201351S.","journal-title":"Chest"},{"key":"119_CR16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.10516","volume":"92","author":"P Prandoni","year":"2007","unstructured":"Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92:199\u2013205.","journal-title":"Haematologica"},{"key":"119_CR17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-137-12-200212170-00008","volume":"137","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137:955\u201360.","journal-title":"Ann Intern Med"},{"key":"119_CR18","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.109.925214","volume":"121","author":"S Eichinger","year":"2010","unstructured":"Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:1630\u20136.","journal-title":"Circulation"},{"key":"119_CR19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.160.6.769","volume":"160","author":"PO Hansson","year":"2000","unstructured":"Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769\u201374.","journal-title":"Arch Intern Med"},{"key":"119_CR20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699\u2013708.","journal-title":"N Engl J Med"},{"key":"119_CR21","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499\u2013510.","journal-title":"N Engl J Med"},{"key":"119_CR22","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR Buller","year":"2012","unstructured":"EINSTEIN-PE Investigators, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287\u201397.","journal-title":"N Engl J Med"},{"key":"119_CR23","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342\u201352.","journal-title":"N Engl J Med"},{"key":"119_CR24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709\u201318.","journal-title":"N Engl J Med"},{"key":"119_CR25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799\u2013808.","journal-title":"N Engl J Med"},{"key":"119_CR26","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR B\u00fcller","year":"2013","unstructured":"Hokusai-VTE Investigators, B\u00fcller HR, D\u00e9cousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406\u201315.","journal-title":"N Engl J Med"},{"key":"119_CR27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764\u201372.","journal-title":"Circulation"},{"key":"119_CR28","doi-asserted-by":"crossref","unstructured":"Raskob G, Buller H, Prins M et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study. J Thromb Haemost 2013;11:1287\u201394.","DOI":"10.1111\/jth.12230"},{"key":"119_CR29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","volume":"116","author":"G Agnelli","year":"2007","unstructured":"Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation. 2007;116:180\u20137.","journal-title":"Circulation"},{"key":"119_CR30","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1532-5415.2006.00828.x","volume":"54","author":"MC Fang","year":"2006","unstructured":"Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54:1231\u20136.","journal-title":"J Am Geriatr Soc"},{"issue":"Suppl 1","key":"119_CR31","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1002\/ajh.23128","volume":"87","author":"JA Heit","year":"2012","unstructured":"Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol. 2012;87(Suppl 1):S63\u20137.","journal-title":"Am J Hematol"},{"key":"119_CR32","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2011.04507.x","volume":"9","author":"J Beyer-Westendorf","year":"2011","unstructured":"Beyer-Westendorf J, Buller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J Thromb Haemost. 2011;9:2153\u20138.","journal-title":"J Thromb Haemost"},{"key":"119_CR33","doi-asserted-by":"crossref","first-page":"e42269","DOI":"10.1371\/journal.pone.0042269","volume":"7","author":"PM Erkens","year":"2012","unstructured":"Erkens PM, ten Cate H, Buller HR, Prins MH. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS ONE. 2012;7:e42269.","journal-title":"PLoS ONE"},{"key":"119_CR34","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s12325-010-0056-z","volume":"27","author":"SB Deitelzweig","year":"2010","unstructured":"Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D. Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther. 2010;27:623\u201333.","journal-title":"Adv Ther"},{"key":"119_CR35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.167.3.229","volume":"167","author":"SE Kimmel","year":"2007","unstructured":"Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007;167:229\u201335.","journal-title":"Arch Intern Med"},{"key":"119_CR36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beha.2013.07.009","volume":"26","author":"R Shameem","year":"2013","unstructured":"Shameem R, Ansell J. Disadvantages of VKA and requirements for novel anticoagulants. Best Pract Res Clin Haematol. 2013;26:103\u201314.","journal-title":"Best Pract Res Clin Haematol"},{"key":"119_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1477-9560-7-3","volume":"7","author":"CD Gonzalez","year":"2009","unstructured":"Gonzalez CD, Bolanos R, de Sereday M. Editorial on hypothesis and objectives in clinical trials: superiority, equivalence and non-inferiority. Thromb J. 2009;7:3.","journal-title":"Thromb J"},{"key":"119_CR38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jhep.2007.02.015","volume":"46","author":"E Christensen","year":"2007","unstructured":"Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol. 2007;46:947\u201354.","journal-title":"J Hepatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0119-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T07:09:24Z","timestamp":1565420964000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0119-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["119"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0119-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}